Table 5.
Patients in whom new information was found after complete sampling
| Number of cases | Biopsy | Prostatectomy | PSA course after RARP | Follow-up (months)—mean | ||||
| Initial PSA—mean | cT stage | Gleason score | pT (N) stage | Margin (R0, R1) | Gleason score | |||
| 1 | 13.0 | T2b | GG-1 | T3b | R1 | GG-2 | Rising PSA: 0.1 and 0.2 at 19 months | 36.0 |
| 11 | 10.3 | T1c-T2a | GG1-3 | T2-T3b | R0-1 | GG1-3 | PSA<0.1 | 35.2 |
| Case | Biopsy | Prostatectomy | Change* | PSA course after RARP | Follow-up (months) | ||||
| Initial PSA | cT stage | Gleason score | pT(N) stage | Margin (R0, R1) | Gleason score | ||||
| 1 | 13 | T2b | 3+3=6, GG-1 | T3b | R1 | 3+4=7, GG-2 | R0>R1 3 mm Gl3 | Rising PSA: 0.1 and 0.2 at 19 months | 36 |
| 2 | 7 | T2a | 3+3=6, GG-1 | T2 | R1 | 3+4=7, GG-2 | R0>R1 1 mm Gl3 | PSA<0.1 | 41 |
| 3 | 6 | T1c | 3+4=7, GG-2 | T2 | R1 | 3+4=7, GG-2 | R0>R1 3 mm Gl3 | PSA<0.1 | 26 |
| 4 | 11 | T2a | 4+5=9, GG-5 | T3b N1 | R1 | 4+3=7, GG-3 | R0>R1 1 mm Gl4 | PSA<0.1 | 42 |
| 5 | 4 | T2a | 3+3=6, GG-1 | T2 | R1 | 3+3=6, GG-1 | R0>R1 1 mm Gl3 | PSA<0.1 | 42 |
| 6 | 20 | T1c | 4+3=7, GG-3 | T3b N1 | R1 | 3+4=7, GG-2 | R0>R1 2 mm Gl3 | PSA<0.1 | 34 |
| 7 | 9 | T2a | 3+3=6, GG-1 | T2 | R1 | 3+3=6, GG-1 | R0>R1 2 mm Gl3 | PSA<0.1 | 40 |
| 8 | 8 | T1c | 3+3=6, GG-1 | T3a | R1 | 3+3=6, GG-1 | R0>R1 1 mm and Gl3 and PT2>pT3a 0.7 mm | PSA<0.1 | 39 |
| 9 | 14 | T2a | 3+3=6, GG-1 | T3a | R1 | 3+3=6, GG-1 | PT2>pT3a 0.5 mm | PSA<0.1 | 31 |
| 10 | 6 | T2a | 3+4=7, GG-2 | T3a N1 | R0 | 3+4=7, GG-2 | PT2>pT3a 1 mm | PSA<0.1 | 30 |
| 11 | 8 | T1c | 4+3=7, GG-3 | pT3a N0 | R1 | 4+3=7, GG-3 | PT2>pT3a 1 mm | PSA<0.1 | 36 |
| 12 | 20 | T2a | 3+3=6, GG-1 | T3a | R1 | 4+3=7, GG-3 | PT2>pT3a 1 mm | PSA<0.1 | 26 |
*Extent of involved margin in millimetre (mm); Gleason grade (Gl) at margin.
GG, grade group; RRAP, robot-assisted radical prostatectomy.